Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.

Cell chemical biology - 19 Dec 2024

Kotagiri Sasikumar, Blazanin Nicholas, Xi Yuanxin, Han Yanyan, Qudratullah Md, Liang Xiaobing, Wang Yawen, Pandey Poonam, Mazhar Hira, Lam Truong Nguyen, Singh Anand Kamal, Wang Jing, Lissanu Yonathan

Abstract excerpt

Genomic studies have identified frequent mutations in subunits of the SWI/SNF (switch/sucrose non-fermenting) chromatin remodeling complex including SMARCA4 and ARID1A in non-small cell lung cancer (NSCLC). Genetic evidence indicates that the paralog SMARCA2 is synthetic lethal to SMARCA4 suggesting SMARCA2 is a valuable therapeutic target. However, the discovery of selective inhibitors of SMARCA2 has been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to DNA Helicases

Share to Mice, Nude

Share to Molecular Structure

Share to Nuclear Proteins

Share to Structure-Activity Relationship

Source

Open in PubMed Open full text

Identifiers

PMID: 39378885
DOI: 10.1016/j.chembiol.2024.09.004
PMCID: PMC11663135

Genes

SMARCA2
SMARCA4
ARID1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer.PMID 39378885Read ↗

PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated Cancers.Semantic proximity Read ↗

<i>SMARCA4</i> mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapySemantic proximity Read ↗

The role of SMARCA4 in lung cancerSemantic proximity Read ↗

Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients.Semantic proximity Read ↗

SMARCA4: Current status and future perspectives in non-small-cell lung cancerSemantic proximity Read ↗

Mutation of SMARCA4 Induces Cancer Cell-Intrinsic Defects in the Enhancer Landscape and Resistance to Immunotherapy.Semantic proximity Read ↗

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancerSemantic proximity Read ↗

Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.Semantic proximity Read ↗

Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapySemantic proximity Read ↗

Synthetic lethality: targeting the SMARCA2 bromodomain for degradation in SMARCA4-deficient tumors – a review of patent literature from 2019–June 2023Semantic proximity Read ↗

SMARCA4 supports the oncogenic landscape of <i>KRAS</i> -driven lung tumorsSemantic proximity Read ↗

SMARCA4 and SMARCA2 co-deficiency: An uncommon molecular signature defining a subset of rare, aggressive and undifferentiated malignancies associated with defective chromatin remodelingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.